Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

Japan’s Mao Matsuyama, 16, holds no relation to a star fellow countryman – but he’s chasing a similar stature in the game of golf. “I often get asked if we are brothers or related,” he ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared ... as this exposure definition aligns with the hypothesised biological ...

USA: A recent study published in JAMA Internal Medicine has evaluated the comparative effectiveness of individual sodium-glucose cotransporter 2 (SGLT-2) inhibitors in treating type 2 diabetes ...

Calorie restriction, physical activity and the drug dapagliflozin caused 44% of participants in a small trial to enter diabetes remission Dapagliflozin is a sodium glucose co-transporter 2 (SGLT2) ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much ...

SGLT2 inhibitor use might be renoprotective in patients with ADPKD, but could increase kidney volume. Dapagliflozin might help protect kidney function in patients with autosomal dominant polycystic ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

Experts say the kuranui, otherwise known as moa, played a vital part in sustaining rākau Māori, crucial to the wellbeing of the taiao and the Māori language. The kuranui, otherwise known as moa ...

If you continue to have this issue please contact customerservice@slackinc.com. Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also ...

For example, by building on the success of Forxiga (dapagliflozin), the first SGLT2 inhibitor to demonstrate ... the use of the drug in novel dual mechanism combinations across five indications ...